Johnson & Johnson is the latest pharma group to agree a Most-Favoured Nation (MFN) drug pricing agreement with the Trump administration to avert the threat of tariffs. In a statement, the company – thought to be the 15th to sign up to such a deal – said it will deliver improved access to medicines at…
Prospects for Bayer’s oral Factor XIa inhibitor asundexian were looking speculative when it failed a phase 3 trial in atrial fibrillation (AF), but new data in secondary stroke prevention could get the programme back on track. The results of the OCEANIC-STROKE study reveal that asundexian was more effective than placebo when given on top of…
Hopes that anti-tau drugs could join those targeting amyloid as treatments for Alzheimer’s disease have been dented by the failure of a phase 2b trial of Johnson & Johnson’s posdinemab. The AuTonomy study of posdinemab had been designed as a proof-of-concept for the anti-tau antibody in early-stage Alzheimer’s patients, but the drug failed to show…
Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud. You can reach Allison on Signal at AllisonDeAngelis.01. A closely watched next-generation blood thinner being developed by Bristol Myers Squibb and Johnson &…
CDSCO Panel Clears MSN Labs’ Abiraterone Acetate 1000 mg, Mandates Phase IV Trial We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Damian Garde is a reporter at large, live and feature journalism, covering the global drug industry and contributing to STAT’s industry-leading events. Johnson & Johnson won U.S. approval to sell the antipsychotic drug Caplyta as a treatment for depression, the company said Thursday, a major step in the drugmaker’s efforts to make the medicine a…
Johnson & Johnson has suffered a setback in its long-running legal defence against claims its talc products cause cancer. A jury in a Los Angeles, California court has ordered the company to pay an eye-watering $966 million to the family of Mae Moore, who died from the rare lung cancer mesothelioma aged 88 in 2021,…
Megan Molteni reports on discoveries from the frontiers of genomic medicine, neuroscience, and reproductive tech. She joined STAT in 2021 after covering health and science at WIRED. You can reach Megan on Signal at mmolteni.13. It’s been 70 years since Philadelphia-based McNeil Laboratories introduced the first pure acetaminophen product to American consumers: Elixir Tylenol, a…
AbbVie’s purchase of Gilgamesh Pharmaceuticals’ psychedelic compound bretisilocin for up to $1.2 billion last month marked the first time a traditional pharma company has bought an investigational psychedelic drug. The deal suggests pharma is getting more comfortable with psychedelic drugs, despite the Food and Drug Administration’s rejection of MDMA last year. Following the success of…
Delhi Police Cracks Fake Drug Network, Counterfeit Ultracet, Augmentin Seized, 6 Held We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link